Search Results
1
Study Matches
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa: Phase 3 Double-Blind Study. Participation will last approximately 71 weeks. Injection under the skin, Males/Females at least 18 years old with Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa (HS), is an inflammatory skin condition that can come and go. It is characterized by painful spots, called lesions, that are found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring.
The purpose of this study is to find out if the study medicine, bimekizumab, can help with the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
NCT04242446
Skin Conditions